Trionex also known as Calcipotriene Cream, 0.005% And Transparent Dressing is a human prescription drug labeled by 'V2 Pharma, Llc'. National Drug Code (NDC) number for Trionex is 72835-902. This drug is available in dosage form of Kit. The names of the active, medicinal ingredients in Trionex drug includes . The currest status of Trionex drug is Active.

Trionex calcipotriene cream, 0.005% and transparent dressing calcipotriene calcipotriene calcipotriene calcipotriene benzyl alcohol cetostearyl alcohol ceteth-20 sodium phosphate dibasic dihydrate glycerin medium-chain triglycerides mineral oil sodium phosphate, monobasic, monohydrate water petrolatum hydrofilm

Indication and usage indicated for the treatment of plaque psoriasis.

Indications and usage calcipotriene cream, 0.005%, is indicated for the treatment of plaque psoriasis. the safety and effectiveness of topical calcipotriene in dermatoses other than psoriasis have not been established.

Warnings for external use only. avoid contact with eyes, lips or mucous membranes.

Warnings contact dermatitis, including allergic contact dermatitis, has been observed with the use of calcipotriene cream.

General use of calcipotriene cream may cause transient irritation of both lesions and surrounding uninvolved skin. if irritation develops, calcipotriene cream should be discontinued. for external use only. keep out of the reach of children. always wash hands thoroughly after use. reversible elevation of serum calcium has occurred with use of topical calcipotriene. if elevation in serum calcium outside the normal range should occur, discontinue treatment until normal calcium levels are restored.

Dosage and administration apply a thin layer of calcipotriene cream to the affected skin 1-2 times daily and rub in gently and completely. the safety and efficacy of calcipotriene cream have been demonstrated in patients treated for eight weeks. once calcipotriene has been completely rubbed in completely, apply transparent dressing to the affected area as needed as a protectant.

Dosage and administration apply a thin layer of calcipotriene cream to the affected skin twice daily and rub in gently and completely. the safety and efficacy of calcipotriene cream have been demonstrated in patients treated for eight weeks.

Contraindications do not use if known hypersensitivity to any of the listed ingredients of any of the components included on the kit.

Contraindications calcipotriene cream is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. it should not be used by patients with demonstrated hypercalcemia or evidence of vitamin d toxicity. calcipotriene cream should not be used on the face.

Adverse reactions clinical trials experience in controlled clinical trials, the most frequent adverse experiences reported for calcipotriene cream, 0.005% were cases of skin irritation, which occurred in approximately 10 to 15% of patients. rash, pruritus, dermatitis and worsening of psoriasis were reported in 1 to 10% of patients. postmarketing experience because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. the following adverse reactions associated with the use of calcipotriene cream have been identified post-approval: contact dermatitis, including allergic contact dermatitis.

Pregnancy if pregnant or breast feeding, ask a health professional before use.

Pregnancy teratogenic effects: pregnancy category c studies of teratogenicity were done by the oral route where bioavailability is expected to be approximately 40 to 60% of the administered dose. increased rabbit maternal and fetal toxicity was noted at 12 mcg/kg/day (132 mcg/m 2 /day). rabbits administered 36 mcg/kg/day (396 mcg/m 2 /day) resulted in fetuses with a significant increase in the incidences of pubic bones, forelimb phalanges, and incomplete bone ossification. in a rat study, oral doses of 54 mcg/kg/day (318 mcg/m 2 /day) resulted in a significantly higher incidence of skeletal abnormalities consisting primarily of enlarged fontanelles and extra ribs. the enlarged fontanelles are most likely due to calcipotriene's effect upon calcium metabolism. the maternal and fetal calculated no-effect exposures in the rat (43.2 mcg/m 2 /day) and rabbit (17.6 mcg/m 2 /day) studies are approximately equal to the expected human systemic exposure level (18.5 mcg/m 2 /day) from dermal appli Read more...

Pediatric use safety and effectiveness of calcipotriene cream in pediatric patients have not been established. because of a higher ratio of skin surface area to body mass, pediatric patients are at greater risk than adults of systemic adverse effects when they are treated with topical medication.

Geriatric use of the total number of patients in clinical studies of calcipotriene cream, approximately 15% were 65 or older, while approximately 3% were 75 and over. there were no significant differences in adverse events for subjects over 65 years compared to those under 65 years of age. however, the greater sensitivity of older individuals cannot be ruled out.

Overdosage topically applied calcipotriene can be absorbed in sufficient amounts to produce systemic effects. elevated serum calcium has been observed with excessive use of topical calcipotriene. if elevation in serum calcium should occur, discontinue treatment until normal calcium levels are restored (see precautions ).

Trionex description trionex is supplied as 4 components in a kit : -1 tube of calcipotriene cream 0.005%, 60g (ndc 68462-501-65) - 30 sheets of hydrofilm transparent dressing (3 boxes of 10 sheets)

Description calcipotriene cream, 0.005% contains calcipotriene, usp, a synthetic vitamin d 3 derivative, for topical dermatological use. chemically, calcipotriene, usp is (5z,7e,22e,24s)-24-cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1α,3β,24-triol, with the empirical formula c 27 h 40 o 3 , a molecular weight of 412.62 g/mol and the following structural formula: calcipotriene, usp is a white or almost white crystalline powder. calcipotriene cream, 0.005% contains 50 mcg/g anhydrous calcipotriene, usp in a cream base of benzyl alcohol, cetostearyl alcohol, ceteth-20, cetostearyl alcohol, disodium hydrogen phosphate dihydrate, glycerin, medium chain triglycerides, mineral oil, monosodium phosphate monohydrate, purified water and white petrolatum. structural-formula

Clinical pharmacology in humans, the natural supply of vitamin d depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol to vitamin d 3 (cholecalciferol) in the skin. calcipotriene is a synthetic analog of vitamin d 3 . clinical studies with radiolabelled calcipotriene ointment indicate that approximately 6% (± 3%, sd) of the applied dose of calcipotriene is absorbed systemically when the ointment is applied topically to psoriasis plaques, or 5% (± 2.6%, sd) when applied to normal skin, and much of the absorbed active is converted to inactive metabolites within 24 hours of application. systemic absorption of the cream has not been studied. vitamin d and its metabolites are transported in the blood, bound to specific plasma proteins. the active form of the vitamin, 1,25-dihydroxy vitamin d 3 (calcitriol), is known to be recycled via the liver and excreted in the bile. calcipotriene metabolism following systemic uptake is rapid, and occu Read more...

Carcinogenesis, mutagenesis, impairment of fertility when calcipotriene was applied topically to mice for up to 24 months at dosages of 3, 10 and 30 mcg/kg/day (corresponding to 9, 30 and 90 mcg/m 2 /day), no significant changes in tumor incidence were observed when compared to control. in a study in which albino hairless mice were exposed to both uvr and topically applied calcipotriene, a reduction in the time required for uvr to induce the formation of skin tumors was observed (statistically significant in males only), suggesting that calcipotriene may enhance the effect of uvr to induce skin tumors. patients that apply calcipotriene cream to exposed portions of the body should avoid excessive exposure to either natural or artificial sunlight (including tanning booths, sun lamps, etc.). physicians may wish to limit or avoid use of phototherapy in patients that use calcipotriene cream. calcipotriene did not elicit any mutagenic effects in an ames mutagenicity assay, a mouse lymphoma t Read more...

Clinical studies adequate and well-controlled trials of patients treated with calcipotriene cream have demonstrated improvement usually beginning after 2 weeks of therapy. this improvement continued with approximately 50% of patients showing at least marked improvement in the signs and symptoms of psoriasis after 8 weeks of therapy, but only approximately 4% showed complete clearing.

Store at 20°-25°c (68° to 77°f); keep away from heat and flame. protect from freezing. [see usp controlled room temperature.]

Information for patients patients using calcipotriene cream should receive the following information and instructions: 1. this medication is to be used only as directed by the physician. it is for external use only. avoid contact with the face or eyes. as with any topical medication, patients should wash their hands after application. 2. this medication should not be used for any disorder other than that for which it was prescribed. 3. patients should report to their physician any signs of adverse reactions. 4. patients that apply calcipotriene cream to exposed portions of the body should avoid excessive exposure to either natural or artificial sunlight (including tanning booths, sun lamps, etc.).

Principal display panel - kit carton v2 pharma, llc trionex ndc 72835-902-02 rx only trionex packaging